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Abstract
Background: Hyperlactataemia (HL) is a biomarker of disease severity that predicts mortality in patients with sepsis
and malaria. Lactate clearance (LC) during resuscitation has been shown to be a prognostic factor of survival in
critically ill adults, but little data exist for African children living in malaria-endemic areas.
Methods: In a secondary data analysis of severely ill febrile children included in the Fluid Expansion as Supportive
Therapy (FEAST) resuscitation trial, we assessed the association between lactate levels at admission and LC at 8 h
with all-cause mortality at 72 h (d72). LC was defined as a relative lactate decline ≥ 40% and/or lactate
normalisation (lactate < 2.5 mmol/L).
Results: Of 3170 children in the FEAST trial, including 1719 children (57%) with Plasmodium falciparum malaria,
3008 (95%) had a baseline lactate measurement, 2127 (71%) had HL (lactate ≥ 2.5 mmol/L), and 1179 (39%) had
severe HL (≥ 5 mmol/L). Within 72 h, 309 children (10.3%) died, of whom 284 (92%) had baseline HL. After adjustment
for potential confounders, severe HL was strongly associated with mortality (Odds Ratio (OR) 6.96; 95% CI 3.52, 13.76,
p < 0.001). This association was not modified by malaria status, despite children with malaria having a higher baseline
lactate (median 4.6 mmol/L vs 3 mmol/L; p < 0.001) and a lower mortality rate (OR = 0.42; p < 0.001) compared to
non-malarial cases. Sensitivity and specificity analysis identified a higher lactate on admission cut-off value predictive
of d72 for children with malaria (5.2 mmol/L) than for those with other febrile illnesses (3.4 mmol/L).
At 8 h, 2748/3008 survivors (91%) had a lactate measured, 1906 (63%) of whom had HL on admission, of whom 1014
(53%) fulfilled pre-defined LC criteria. After adjustment for confounders, LC independently predicted survival after 8 h
(OR 0.24; 95% CI 0.14, 0.42; p < 0.001). Absence of LC (< 10%) at 8 h was strongly associated with death at 72 h (OR 4.
62; 95% CI 2.7, 8.0; p < 0.001).
Conclusions: Independently of the underlying diagnosis, HL is a strong risk factor for death at 72 h in children
admitted with severe febrile illnesses in Africa. Children able to clear lactate within 8 h had an improved chance of
survival. These findings prompt the more widespread use of lactate and LC to identify children with severe disease and
monitor response to treatment.
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Background
Infection is a leading cause of death in children under 5
years of age in resource-poor countries in Africa, mainly
related to pneumonia, diarrhea, and malaria [1]. Irre-
spective of the underlying aetiology, children with severe
infection in these settings usually present critically ill to
health units with basic facilities, with most deaths occur-
ring within the first 24 h of admission [2]. Immediate
recognition and prompt appropriate resuscitation of
those children at highest risk of death are crucial to im-
prove survival. Clinical criteria have been proposed by
the World Health Organization (WHO) [3, 4], and prac-
tical clinical bedside risk scores have been evaluated to
identify those at greatest risk of death [5]; however, data
on point-of-care diagnostics to refine and target man-
agement at the point of triage are still lacking.
Hyperlactataemia (HL) is a well-known biomarker of
severe disease that strongly predicts death in paediatric
and adult patients with bacterial sepsis and malaria
[6–9]. Its prognostic value, availability of point-of-care
non-invasive testing, and immediate turnaround time
have made lactate measurement one of the most widely
recommended tools for early recognition and risk
stratification of patients with severe sepsis [10–12]. In
malaria-endemic areas, however, the use of point-of-
care lactate measurement is controversial due to lack of
data to support wider implementation [5, 13]. Never-
theless, therapeutic strategies aimed at decreasing lacta-
taemia in serial determinations of lactate clearance
(LC) could be a simple tool and may be clinically more
valuable than initial single lactate measurements, help-
ing to guide resuscitation and potentially being a cost-
effective measure in these settings.
In recent years, several studies including two meta-
analyses have demonstrated that early LC and lactate
normalisation are powerful independent predictors of
survival in critically ill adults [14–17]. Furthermore, two
randomised clinical trials [18, 19] showed that targeting
initial treatment to a pre-specified LC was associated
with non-inferior or even superior outcomes compared
to central venous oxygen saturation, a surrogate marker
of cardiac output and a standard invasive therapeutic
goal in sepsis. To date, however, only a few small studies
have explored the prognostic value of LC in severely ill
children with sepsis or malaria [20–22]. A large multi-
centre randomised control trial of fluid resuscitation
strategies in severely ill febrile children in east Africa,
the Fluid Expansion as Supportive Therapy (FEAST)
trial, ISRCTN69856593 [23], provided a good opportun-
ity to explore this question further.
The main aim of the current study was to assess the
prognostic value of LC at 8 h on all-cause mortality at
72 h (d72) in a large cohort of severely ill febrile children
in a malaria-endemic area. Secondary aims were to
confirm the association between HL and d72, assess if
this was modified by type of severe febrile illness (mal-
aria vs non-malaria), and to determine the cut-off lactate
level on admission that best predicts mortality in these
children.
Methods
The current study is a secondary analysis derived from
the FEAST trial [23]. The overall aim of the trial was to
answer whether rapid expansion of intravascular volume
was safe and improved survival compared to no bolus
(maintenance only). The study was conducted between
January 2009 and January 2011 at six clinical centres, in-
cluding large regional and district hospitals in three east
African countries (Kilifi, Kenya; Muheza, Tanzania; and
Kampala, Mbale, Soroti, and Lacor in Uganda). Malaria
transmission in Kilifi and Muheza was predominantly
seasonal and of moderate intensity during the period of
the trial, whilst transmission at all sites in Uganda was
perennial and intense.
Study population
Children were eligible for the FEAST trial if they were
between 60 days and 12 years of age, had a history of
fever and/or abnormal temperature (pyrexia [≥ 37.5 °C]
or hypothermia [< 36 °C]), and were admitted to hospital
with severe illness (respiratory distress and/or impaired
consciousness) plus at least one of the following signs of
impaired peripheral perfusion: capillary refill time > 2 s;
lower limb temperature gradient (defined as a notable
temperature change from cold [dorsum of foot] to warm
[knee] when running the back of the hand from the toe
to the knee); weak radial pulse; or severe tachycardia
(defined as heart rate > 180 beats per minute [bpm] for
children < 1 year old, > 160 bpm for those 1 to 4 years
old, > 140 bpm for those ≥ 5 years old). Children were
excluded from the trial if they presented with severe
acute malnutrition, gastroenteritis, burns, or surgical
conditions. Children were randomised to receive imme-
diate boluses of 20–40 mL/kg of 5% human albumin so-
lution or 0.9% saline solution over 1 h (intervention
group) following by maintenance fluids, or maintenance
intravenous fluids only at 4 mL/kg/h (control group)
until able to drink. The primary endpoint was mortality
at 48 h after randomisation.
Clinical care
Standardised case report forms were completed at enrol-
ment and at specific time points during the first 48 h. At
enrolment, lactate, haemoglobin, and glucose point-of-
care measurements were conducted, together with an
HIV antibody test, malaria blood film, and a rapid diag-
nostic test for malaria. At 8 h and 24 h, lactate and
haemoglobin measurements were repeated. Lactate was
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measured using a Lactate Pro® (Arkray KDK, Kyoto,
Japan) hand-held analyser, which was calibrated daily,
and each time a new box of Lactate Pro® Test Strips was
used. The test results, available in 60 s, displayed ‘LO’ if
the lactate level was below 0.8 mmol/L and ‘HI’ if the
lactate level was above 23.3 mmol/L. Out-of-range re-
sults were repeated for verification. Haemoglobin was
determined with the HemoCue® Hb 301 system, Angel-
holm, Sweden. Children were managed on general
paediatric wards, with no facilities for ventilation other
than short-term ‘bag-and-mask’ support. Training in tri-
age, identification, and definitions of adverse events re-
lated to fluid management (including transfusion) was
given prior to and throughout the trial and was included
in the trial manual of operations that was given to every
team member. The main outcome of the FEAST trial
[23] and the transfusion practices [24] used in the study
have been reported in detail previously.
Statistical analysis
The current secondary analysis was performed using the
parent study database, cleaned and exported into STATA
version 11 (StataCorp, LP, College Station, TX, USA). All
children in the FEAST dataset with a valid lactate meas-
urement at time of admission were included in the ana-
lysis, with a subsequent analysis of those who also had a
lactate measurement 8 h after admission.
Hyperlactataemia classification and lactate clearance
definition
In the current study, we considered HL as a lactate > 2.5
mmol/L. We sub-categorised patients according to the
lactate level on hospital admission as having moderate
HL (lactate 2.5 to < 5 mmol/L), severe HL (lactate ≥ 5
mmol/L), or no HL (lactate < 2.5 mmol/L). An LC value
was calculated for all children with an increased lactate
level on admission (≥ 2.5 mmol/L) who were alive and
had a lactate measurement at 8 h. Relative LC (percent)
was defined by the equation [(lactate initial − lactate at 8
h)/lactate initial] × 100, for which lactate initial was the
measurement at randomisation. Lactate normalisation
was defined as a lactate decline to < 2.5 mmol/L at 8 h.
The 8-h LC goal was defined by a relative lactate de-
crease of at least 40% from baseline and/or lactate
normalisation.
Baseline clinical characteristics by survival status were
described, combining randomisation groups. Frequencies
and percentages were used for categorical variables, and
medians with their inter-quartile range (IQR) for non-
normally distributed continuous data. Baseline clinical
characteristics were compared across outcome categor-
ies using the chi-squared test or the Wilcoxon signed-
rank test as appropriate. Descriptive analysis reported
both missing and available data.
The main exposure of interest was LC at 8 h. The
primary outcome was all-cause in-hospital mortality
at 72 h of randomisation (d72). As a first step in the
LC analysis, the association between baseline HL
and d72 was examined. For each of the exposures,
HL and LC, the crude odds ratio (OR) with 95%
confidence interval (CI) was calculated for the asso-
ciation with d72. To identify potential confounders,
associations between patient characteristics and ex-
posure and outcome variables were determined.
Classic Mantel-Haenszel methods were used to ex-
plore for confounding and effect modification. A
multivariable logistic regression model was fitted
with a stepwise forward process selection to estimate
the OR adjusted for several covariates simultaneously
using all available data. Candidate variables were se-
lected using previously defined risk factors of mor-
tality and confounders identified in the univariate
analysis. Age, sex, and study site were included a
priori in both models due to their association with a
wide range of health parameters. The effect of the
trial intervention was included as a potential con-
founder and tested as an effect modifier of the asso-
ciation between LC and d72 with increased mortality
in the FEAST trial. Likelihood ratio tests were used
to assess for the model fit.
Receiver operating characteristic (ROC) curve analysis
was used to determine the cut-off value for lactate level
at hospital admission that would best predict death at 72
h. As children with malaria had a higher prevalence of
severe HL despite a lower mortality rate, ROC curves
were also built separately for children with and without
malaria to assess if the best prognostic cut-offs differed
(Fig. 1). A ROC curve was also fitted for d72 based on
the regression model for LC at 8 h.
Fig. 1 ROC curve for mortality at 72 h of randomisation based
on lactate measurement at admission by malaria: 0 = no malaria
and 1 = malaria
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Results
Of 3170 children randomised in the FEAST trial, 3008
(95%) had a lactate measurement on hospital admission
and were included in the current analysis. In this group,
there were 309 deaths (10.3%) in the first 72 h after ran-
domisation, which accounted for 90% of the overall mor-
tality by 28 days. The clinical and laboratory baseline
characteristics of the children by primary outcome are
summarised in Table 1. The median age was 24 months
(IQR 13 to 39), and 1387 (46%) were female. The major-
ity of children presented with respiratory distress (2463,
82%) and/or impaired consciousness (2326, 78%). All
had at least one sign of impaired perfusion, including se-
vere tachycardia (2120, 71%), a prolonged capillary refill-
ing time of 2 s or longer (2030, 67%), or a lower limb
temperature gradient (1777, 59%). Weak radial pulse
volume, present in 635 children (21%) and bradycardia
(in 36 children) were strongly associated with a poor
outcome (unadjusted OR 4.24; 95% CI 3.30, 5.45; p <
0.001 and 13.13; 95% CI 6.62, 26; p < 0.001 respectively).
Severe anaemia (Hb < 5 g/dL) was present in 958 chil-
dren (33%) at admission. Plasmodium falciparum mal-
aria was confirmed in 1719 children (57%) and HIV
infection in 106 (4%) of the 2417 children tested. A
blood culture was positive in 123 (12%) of the 1052 chil-
dren in whom the test was performed.
Baseline lactate level and mortality
At hospital admission 2127 children (71%) had a raised
baseline lactate (≥ 2.5 mmol/L). Of these, 948 children
(32%) had moderate HL (lactate 2.5 to < 5 mmol/L) and
1179 (39%) had severe HL (lactate ≥ 5 mmol/L). Chil-
dren with severe HL had a higher prevalence of other
clinical and laboratory markers of disease severity, in-
cluding hypoxaemia (SpO2 < 90% by pulse oximetry) (p <
0.001), coma (p < 0.001), severe anaemia (p < 0.001), or
severe acidosis (p < 0.001). Children with malaria para-
sitaemia had higher mean baseline lactate (4.6 vs 3
mmol/L, p < 0.001) and prevalence of severe HL (46% vs
30%, p < 0.001) than those with other febrile illnesses.
Of the 309 children who died in the first 72 h, 238
(77%) had severe HL on admission and 46 (15%) had
moderate HL. The median admission lactate in children
who died was significantly higher (10.9 mmol/L; IQR
5.2–13.6) than in those who survived the first 72 h (3.4
mmol/L; IQR 2.2–6.9) (p < 0.001). Amongst those chil-
dren who died, the median admission lactate was higher
when death occurred in the first 8 h (12.2 mmol/L; IQR
8.6–13.9) than when it occurred between 8 and 72 h
(7.65 mmol/L; IQR 4.1–12.6) or after 72 h (3.2 mmol/L;
IQR 2.1–5.2) of the admission respectively.
In the univariate analysis, baseline severe HL strongly
increased the odds of death at 72 h (OR 8.66; 95% CI
5.7, 13.2), whilst moderate HL had a weaker effect on
mortality (OR 1.75; 95% CI 1.06, 2.87). This association
did not significantly vary amongst children with and
without malaria, indicating that severe HL was equally
prognostic for both conditions. Evidence for an effect
modification, however, was found between HL and
hyperglycaemia (glucose ≥ 8.3 mmol/L) (heterogeneity
test p < 0.01), elevated blood urea nitrogen (BUN) (het-
erogeneity test p < 0.001), and presence of crackles on
auscultation (heterogeneity test p = 0.025) (Additional
file 1: Supplementary tables).
After full adjustment for confounders (Table 2), severe
HL on hospital admission remained strongly associated
with death at 72 h (OR 6.96; 95% CI 3.52, 13.76), whilst
moderate HL showed a weaker association (OR 1.57;
95% CI 0.80, 3.08).
Coma was a strong independent risk factor (OR 6.87;
95% CI 3.36, 14.04), and elevated BUN and HIV infec-
tion were moderately strong independent risk factors of
death identified in the model. Whilst a positive malaria
test appeared to be more strongly associated with higher
likelihood of survival, this cannot be interpreted as a
protective effect of parasitaemia per se, since the model
was controlling for other factors which are likely im-
pacted by malaria and strongly associated with mortality.
The multivariable regression model accounting for the
interaction between HL and hyperglycaemia demon-
strated a weakened association between HL and mortal-
ity in the presence of hyperglycaemia (OR 3.22; 95% CI
1.56, 6.67; p < 0.01), although the effect of HL on the
risk of mortality in the absence of hyperglycaemia (OR
8.55; 95% CI 4.63, 15.78; p < 0.001) was slightly greater.
Furthermore, logistic regression analysis accounting for
the additional interactions identified demonstrated that
the association of HL with d72 was considerably lower
in the 427 children (21%) with high admitting BUN (OR
2.33; 95% CI 1.11, 4.89; p = 0.025) and much higher in
the 655 children (22%) with crackles on auscultation
(OR 29.45; 95% CI 10.13, 85.55; p < 0.001) (Additional
file 1).
Lactate clearance at 8 h and mortality
Of all children included in the analysis, 2748/3008
(91.4%) were alive and had a blood lactate level mea-
sured at 8 h of randomisation; 1906 (63.3%) of these had
an elevated lactate level (≥ 2.5 mmol/L) on admission
and contributed to the LC analysis. Table 3 summarises
the absolute and relative LC and lactate normalisation
parameters at 8 h by primary outcome. Overall, the me-
dian lactate at 8 h was 3.4 mmol/L (IQR 2.3–5.1), the
median absolute LC (change from baseline in lactate
level) was 1.6 mmol/L (IQR 0.1–4.6), and the median
relative LC (from baseline value) was 36% (IQR 3.3–
59%). Children who survived to 72 h had a lower median
lactate (3.3 vs 5.4 mmol/L, p < 0.001) and a higher
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Table 1 Clinical and laboratory characteristics on admission by in-hospital mortality at 72 h
Survivors Non-survivors Total Unadjusted OR of death (95% CI) p valuea
Number, N (%)b 2699 (90) 309 (10) 3008 – –
General
Female 1240/2699 (46) 147/309 (5) 1387/3008 (46) 1.07 (0.84, 1.35) 0.59
Age (months); median (IQR)c 24 (14, 39) 23 (11, 38) 24 (13, 38.5) – 0.77d
Age < 12 months 494/2699 (16) 83/309 (3) 577/3008 (19) 1.64 (1.25, 2.15) < 0.001
Middle-arm circumference ≤ 11.5 cm 56/2644 (1.95) 13/199 (0.5) 69/2843 (2.4) 3.23 (1.73, 6) < 0.001
Axillary temperature > 39 °C 658/2694 (22) 45/309 (1) 703/3003 (23) 0.62 (0.44, 0.86) < 0.01
Hypothermia (temperature < 36 °C) 133/2694 (4) 53/309 (2) 186/3003 (6) 3.99 (2.82, 5.64) < 0.001
Respiratory
Respiratory rate; median (IQR)c 57 (48, 67) 60 (50, 70) 57 (48, 67) – 0.03d
Respiratory distress 2183/2688 (73) 280/308 (9) 2463/2996 (82) 2.31 (1.55, 3.46) < 0.001
Deep breathing 1674/2697 (56) 261/308 (8) 1935/3005 (64) 2.47 (1.95, 3.14) < 0.001
Hypoxaemia (oxygen saturation ≤ 90%) 521/2626 (18) 113/271 (4) 634/2897 (22) 2.89 (2.22, 3.76) < 0.001
Crackles on auscultation 543/2697 (18) 112 /308 (4) 655/3005 (22) 2.27 (1.76, 2.92) < 0.001
Cardiovascular
Severe tachycardiae 1955 /2697(73) 165/308 (54) 2120/3005 (71) 0.44 (0.34, 0.56) < 0.001
Bradycardia 15/2698 (0.6) 2/3071 (7) 36/3005 (1.2) 13.13 (6.62, 26) < 0.001
Capillary refill time:
< 2 s 921/2696 (34) 53/308 (17) 974/3004 (32) 1.00 (Ref.)f
2–3 s 1130/2696 (42) 109/308 (35) 1239/3004 (41) 2.50 (1.83, 3.40) < 0.001
≥ 3 s 645/2696 (24) 146/308 (47) 791/3004 (26) 2.87 (2.25, 3.66) < 0.001
Lower limb temperature gradientg 1544/2699 (57) 233/309 (75) 1777/3008 (59) 2.29 (1.75, 3.01) < 0.001
Weak radial pulse 486/2699 (18) 149/309 (48) 635/3008 (21) 4.24 (3.30, 5.45) < 0.001
Moderate hypotensionh 162/2664 (6) 40/289 (14) 202/2953 (7) 2.48 (1.71, 3.60) < 0.001
Dehydration (sunken eyes or reduced skin turgor) 178/2697 (7) 51/307 (17) 229/3004 (8) 2.82 (2.01, 3.96) < 0.001
Neurological
Level of consciousness:
Alert 657 /2696(24) 22/309 (7) 679/3005 (23) 1.00 (Ref.)f
Prostratei 1714/2696 (64) 171/309 (55) 1885/3005 (63) 2.98 (1.89, 4.69) < 0.001
Comaj 325/2696 (12) 116/309 (38) 441/3005 (15) 10.66 (6.63, 17.14) < 0.001
Convulsions in this illness 301/2698 (11) 48/309 (16) 349/3007 (12) 1.40 (1.00, 1.95) 0.05
Clinical anaemia
Severe pallork 969/2694 (36) 170 /309(55) 1139/3003 (38) 2.18 (1.71, 2.77) < 0.001
Haemoglobinuria (history of dark urine) 339/2694 (1.4) 40/307 (13) 379/3001 (13) 1.21 (0.95, 1.54) 0.13
Jaundice 833/2695 (31) 133/309 (43) 966/3004 (32) 1.65 (1.30, 2.10) < 0.001
Laboratory tests
Lactate (mmol/L); median (IQR)c 3.4 (2.2, 6.9) 10.9 (5.2, 13.6) 3.8 (2.3, 8) – < 0.001d
Hyperlactataemia (lactate, mmol/L)
No (< 2.5) 856/2699 (32) 25/309 (8) 881/3008 (29) 1.00 (Ref.)f
Moderate (2.5–5) 902/2699 (33) 46/309 (15) 948/3008 (32) 1.75 (1.06, 2.87) 0.03
Severe (≥ 5) 941/2699 (35) 238/309 (77) 1179/3008 (39) 8.66 (5.6, 13.4) < 0.001
Severe acidaemia:
pH < 7.2 138/1816 (8) 70/208 (34) 208/2024 (10) 6.17 (4.35, 8.74) < 0.001
Base deficit > −8 mmol/L 869/1809 (48) 170/203 (84) 1039/2012 (58) 5.57 (3.76, 8.26) < 0.001
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relative LC (37% vs 17%, p < 0.01) at 8 h. Median rela-
tive LC was significantly higher in children with severe
HL (54%; IQR 28–70) than in those with moderate HL
(15%; IQR −19 to 38) (p < 0.001). Children with malaria
had a similar relative LC as those with other severe fe-
brile illnesses (37% vs 35%, p = 0.4).
At 8 h, 566 children (30%) had a relative LC < 10%,
whereas a total of 1014 (53%) met the pre-defined LC
criteria (LC decline ≥ 40% [878, 46%] and/or lactate nor-
malisation [< 2.5 mmol/L] [554, 29%]). After full adjust-
ment for confounders, including the effects of lactate
level on admission and the FEAST trial (fluid) interven-
tion arm, failure to clear lactate (LC < 10%) at 8 h of
treatment was strongly associated with death at 72 h
(OR 4.62; 95% CI 2.7, 8; p < 0.001). Furthermore, achiev-
ing the combined LC pre-defined goal was the strongest
prognostic factor of survival (OR 0.24; 95% CI 0.14, 0.42;
p < 0.001) compared to relative LC or lactate normalisa-
tion alone (Table 4).
Persistent severe HL at 8 h remained a strong inde-
pendent risk factor of death at 72 h (OR 4.60; 95% CI
2.61–8.1; p < 0.001). Of note, as previously demon-
strated in the FEAST trial, fluid boluses were strongly
associated with death at 72 h (OR 2.48; 95% CI 1.36,
4.51; p < 0.01) in the full-adjusted logistic regression
model.
ROC analysis and lactate cut-offs
The area under the receiver operator curve (AUROC)
for d72 based on lactate at admission was 0.77 (95% CI
0.74–0.80), with no statistically significant difference in
AUROC amongst children with and without malaria (p
= 0.47) (Fig. 1). The AUROC based on lactate at 8 h was
0.73 (95% CI 0.68–0.77), with again no difference by
malaria status (p = 0.55). The overall AUROC based on
LC at 8 h was 0.58 (95% CI 0.53–0.64), and for the
group of children with severe HL (> 5 mmol/L) on ad-
mission it was greater (0.68; 95% CI 0.62–0.75). Lastly,
the AUROC for d72 based on a logistic regression model
for LC at 8 h was even more predictive as 0.84 (95% CI
0.80–0.88) (Fig. 2).
Sensitivity and specificity analysis identified that for
children without falciparum malaria a lactate level on
admission of ≥ 3.4 mmol/L had a sensitivity to predict
mortality at 72 h of 80% and a specificity of 61.6%,
whereas for children with malaria a sensitivity of 80%
corresponded with a lactate cut-off value of 5.2 mmol/L
(specificity of 59.2%). For a baseline lactate level of ≥ 5
Table 1 Clinical and laboratory characteristics on admission by in-hospital mortality at 72 h (Continued)
Survivors Non-survivors Total Unadjusted OR of death (95% CI) p valuea
Bicarbonate < 15 mmol/L 588/1808 (3) 151/206 (73) 739/2014(37) 5.69 (4.07, 7.97) < 0.001
Haemoglobin (g/dL): 2930
≥ 10 648/2628 (25) 42/302 (14) 690/2930 (24) 1.00 (Ref.)f
7 to < 10 720/2628 (27) 80/302 (27) 800/2930 (27) 1.71 (1.16, 2.53) < 0.01
5 to < 7 437/2628 (17) 45/302 (15) 482/2930 (16) 1.59 (1.02, 2.46) 0.04
< 5 823 /2628(31) 135/302 (45) 958/2930 (33) 2.53 (1.76, 3.64) < 0.001
Glucose (mmol/L); median (IQR)c 6.9 (5.5, 8.70) 5.95 (3.6, 9.1) 6.9 (5.4, 8.7) – < 0.001d
Hypoglycaemia (glucose < 2.5 mmol/L) 82/2615 (3) 48 /300(16) 130/915 (4) 5.88 (4.00, 8.66) < 0.001
Blood urea nitrogen (BUN) ≥ 7.14 mmol/L 337/1819 (19) 90/205 (44) 427/2024 (21) 3.44 (2.54, 4.67) < 0.001
Hyperkalaemia (≥ 6 mmol/L) 50/1768 (3) 37 /197(19) 87/1965 (4) 7.90 (4.98, 12.7) < 0.001
Microbiology
Malaria parasitaemia, positivel 1571/2695 (58) 148/307 (48) 1719/3002 (57) 0.67 (0.53, 0.84) < 0.001
HIV antibody, positive 86/2197 (4) 20/220 (9) 106/2417(4) 2.46 (1.48, 4.08) < 0.001
Blood culture, positive 106/947 (11) 17/105 (16) 123 /1052 (12) 1.53 (0.88, 2.68) 0.13
aChi-squared test p values
bOf 3170 children enrolled in the FEAST trial, 162 did not have lactate measured at baseline
cIQR: percentile 25, percentile 75
dWilcoxon rank sum test p value
eSevere tachycardia was defined as > 180 beats per minute (bpm) in children < 12 months, > 160 bpm in children aged 12 months to 5 years, and > 140 bpm for
those aged > 5 years
fRef: Reference group
gTemperature gradient was assessed by running the back of the hand from the toe to the knee; a positive temperature gradient was defined as a notable
temperature change from cold (dorsum of foot) to warm (knee)
hModerate hypotension was defined as systolic blood pressure of 50–75 mmHg in children younger than 12 months, 60–75 mmHg in those 12 months to years,
and 70–85 mmHg in those older than 5 years, as measured by automated blood pressure monitor
iProstration was defined as the inability of a child older than 8 months of age to sit upright or the inability of a child 8 months of age or younger to breast feed
jComa was defined as the inability to localise a painful stimulus
kPallor manifested in lips, gums, or inner eyelids
lPositive on quality-controlled malaria slide, or, if missing, on rapid diagnostic test
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mmol/L, the sensitivity in children without malaria was
71.7% (specificity 75.53%), whereas in those with malaria
it was 82.43% (specificity 57.7%). This indicates that in
non-malaria cases, lower levels of HL have a similar ef-
fect on 72-h mortality.
Discussion
Our study confirms the association between HL on hos-
pital admission and mortality, and it demonstrates that a
failure to clear lactate (relative LC < 10%) within the first
8 h of treatment is a relevant prognostic factor of early
death in severely ill febrile children in a malaria-endemic
area irrespective of the underlying diagnosis (malaria,
sepsis, or other severe febrile illness). Importantly, this is
the first paediatric study to demonstrate that a relative
LC ≥ 40% and/or lactate normalisation within the first 8
h of treatment strongly predicts 72-h survival in this
context.
These results, derived from a very large multicentre ran-
domised trial, are compelling and raise the question of
whether LC could be a simple, valid and cost-effective risk-
stratification tool, as well as a potential therapeutic target to
guide resuscitation in children with severe febrile illnesses
in resource-poor settings. Furthermore, it is not limited to
children with specific diagnoses, but rather covers different
presentation syndromes, which reflects the population of
children presenting to hospital in the setting in which the
trial was conducted. Lastly, for research studies the inclu-
sion of lactate level could be used for inter-site or inter-
centre comparisons of disease severity.
Despite a paucity of paediatric data, our findings are
supported by the literature. A recent meta-analysis [25]
Table 2 Multivariate analysis (logistic regression model) of clinical and laboratory factors at admission associated with mortality at
72 h of randomisation
Categories Adjusted OR of death (95% CI) p valuea
Age (months) ≥ 12 1.00 (Ref.)b < 0.01
< 12 1.98 (1.22, 3.2)
Gender Male 1.00 (Ref.)b 0.96
Female 1.01 (0.71, 1.46)
Site Mbale 1.00 (Ref.)b
Kilifi 1.56(0.76, 3.23) 0.23
Mulago 1.47 (0.80, 2.70) 0.21
Soroti 1.16 (0.64, 2.14) 0.63
Lacor – –
Teule 2.04 (0.87, 4.76) 0.10
Lactate stratum (mmol/L) No (< 2.5) 1.00 (Ref.)b
Moderate (2.5–5) 1.28 (0.62, 2.63) 0.50
Severe (≥ 5) 6.96 (3.52, 13.76) < 0.001
Level of consciousness Alert 1.00 (Ref.)b
Prostration 1.41 (0.72, 2.76) 0.31
Coma 6.87 (3.36, 14.04) < 0.001
BUN (mmol/L)d < 7.14 1.00 (Ref.)b < 0.001
≥ 7.14 2.92 (1.84, 4.62)
Malaria No 1.00 (Ref.)b < 0.001
Yes 0.45 (0.29, 0.69)
Severe anaemia (Hb < 5 g/dL) No 1.00 (Ref.)b 0.37
Yes 0.81 (0.50, 1.29)
Hyperglycaemiac (glucose ≥ 8.3 mmol/L) No 1.00 (Ref.)2 0.55
Yes 0.84 (0.55, 1.30)
HIV No 1.00 (Ref.)2 0.05
Yes 2.16 (1.01, 4.60)
aWald test p values
bRef: Reference group
cModerate evidence of interaction, stratum-specific odds ratios are shown in Additional file 1
dBlood Urea Nitrogen
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and a large systematic review [17] of acutely ill adults
have reported a consistent lower mortality associated
with LC, not limited to septic patients and regardless of
the initial lactate value. Also, a recent secondary analysis
of two large clinical trials on antimalarials has shown
that lack of LC is an independent predictor of death in
adults with severe malaria [26]. Amongst the few paedi-
atric studies published, Krishna and colleagues measured
serial lactate concentrations during 24 h in a small co-
hort of 115 children with severe malaria in the Gambia,
concluding that sustained HL was the most powerful
prognostic indicator of fatal outcome [21]. In another
cohort of 65 children admitted to a paediatric intensive
care unit (PICU) with septic shock in South Korea, Kim
et al. [22] found that the area under the curve (AUC) of
serial lactates measured during the first 24 h had a
strong predictive power of mortality at 28 days (ROC
AUC 0.828). Munde et al. [27] recently reported that a
relative LC < 30% at 6 h predicted mortality in PICU
children in India comparably to the more complex
Paediatric Risk of Mortality (PRISM) score, standard in
paediatric intensive care.
It is therefore possible that failure to clear lactate
within the first hours of therapy could serve as a simpler
risk stratification tool in malaria-endemic areas,
potentially more reliable than absolute lactate values
alone and easier to apply than more complex clinical
scores. However, to have an outcome benefit, a similar
lack of LC effect should likely be shown at an interval
shorter than 8 h that would allow a therapeutic interven-
tion or the appropriate recruitment into clinical trials of
those children with a higher chance to die.
Moreover, to demonstrate an association between LC
and survival in severely ill febrile children in a malaria-
endemic area is relevant at least in two aspects. On one
hand, LC could serve as a valid surrogate endpoint of
clinical trials of malaria aiming to improve mortality, as
recently demonstrated by Jeeyapant et al. in a large co-
hort of adult patients with malaria [26]. Thus, one could
hypothesise that LC might help to guide the initial re-
suscitation of these children in a resource-poor setting,
where invasive monitoring and intensive care is mostly
unavailable. To date two multicentre randomised trials
have assessed the clinical value of resuscitation strategies
that included LC as a target in adults admitted to inten-
sive care units, showing that quantitative resuscitation
based on LC was non-inferior or even superior to that
based on ScvO2 alone [18, 19], and the most recent Sur-
viving Sepsis Campaign guidelines suggest targeting re-
suscitation to lactate normalisation in adult septic
Table 3 Lactate clearances within first 8 h of randomisation in survivors and non-survivors at 72 h
Survivors Non-survivors Total Unadjusted OR of death (95% CI) p valuea
Lactate clearance at 8 h amongst children with an abnormal lactate on admission ≥ 2.5 mmol/Lb
Number, N (%) 1792 (94) 114 (6) 1906 – –
Lactate at 8 h (mmol/L); median (IQR)c 3.3 (2.3, 5) 5.4 (3.4, 10) 3.4 (2.3, 5.1) – < 0.001d
Absolute LC (mmol/L); median (IQR)c 1.7 (0.2, 4.5) 1.3 (−0.5, 4.7) 1.6 (0.1, 4.6) – 0.12d
Relative LC (%); median (IQR)c 37 (3.7, 59.5) 17 (−6, 51) 36 (3.33, 59) – 0.003d
Relative LC < 10% 516/1792 (29) 50/114 (44) 566/1906 (30) 1.93 (1.31, 2.84) < 0.001
Relative LC ≥ 40% 840/1792 (47) 38/114 (33) 878/1906 (46) 0.57 (0.38, 0.85) < 0.01
Lactate normalisatione 540/1792 (30) 14/114 (12) 554/1906 (29) 0.33 (0.18, 0.57) < 0.001
Relative LC ≥ 40% and/or lactate normalisation 973/1792 (54) 41/114 (36) 1014/1906 (53) 0.47 (0.32, 0.70) < 0.001
Lactate clearance at 8 h amongst those with lactate on admission ≥ 5 mmol/Lf
N (%) 919 (92) 85 (8) 1004 – –
Lactate at 8 h; median (IQR)c 3.9 (2.7, 6) 6.8 (4.1, 11.3) 4.1 (2.8, 6.3) – < 0.001d
Absolute LC (mmol/L); median (IQR)c 4.4 (2.4, 7.7) 2.3 (0, 5.8) 4.3 (2.3, 7.6) – < 0.001d
Relative LC (%); median (IQR)c 55 (32, 71) 23 (0, 62) 54 (28, 70) – < 0.001d
Relative LC < 10% 116 /919(13) 33/85 (39) 149/1004 (15) 4.40 (2.70, 7.16) < 0.001
Relative LC ≥ 40% 628/919 (68) 33/85 (39) 661/1004 (66) 0.29 (0.18, 0.47) < 0.001
Lactate normalisatione 200/919 (22) 6/85 (7) 206/1004 (21) 0.27 (0.12, 0.64) 0.001
Relative LC ≥ 40% and/or lactate normalisation 628/919 (68) 33/85 (39) 661/1004 (66) 0.29 (0.18, 0.47) < 0.001
aChi-squared test p values
bTotal of 811 children with normal lactate levels on admission (< 2.5 mmol/L) excluded
cRef: Reference group
dWilcoxon rank-sum test p values
eLactate decline < 2.5 mmol/L in the first 8 h after randomisation
f1713 children with lactate levels on admission < 5 mmol/L excluded
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patients with HL, although accept a weak evidence exists
for this recommendation [28].
Unfortunately, the observational design of our study
does not allow one to answer whether targeting resusci-
tation to achieve a specific relative LC or lactate normal-
isation improves outcomes in severely ill febrile children
in this context. Interestingly, a recent study including
218 adult patients with severe infection at a regional re-
ferral hospital in Uganda [29] questioned whether serial
assessment of vital signs combined with point-of-care
lactate at 6 h could be a feasible method of monitoring
patients being resuscitated from severe sepsis or malaria
in a resource-poor setting. Despite an improvement in
vital signs and lactate values at 6 h of resuscitation, the
authors could not demonstrate an association between
an LC ≥ 10% and improved in-hospital mortality. This
study, however, was observational with a limited sample
size where more than half of the participants had
Table 4 Multivariable analysis of clinical and laboratory factors associated with death at 72 h including LC at 8 h post-randomisation
Categories Adjusted OR of death (95% CI) p valuea
LC criteriab at 8 h No 1.00 (Ref.)c < 0.001
Yes 0.24 (0.14, 0.42)
Hyperlactataemia on admission (≥ 5 mmol/L) No 1.00 (Ref.)c < 0.001
Yes 6.61 (3.56, 12.30)
FEAST fluid intervention arm Control 1.00 (Ref.)c < 0.01
Fluid bolus 2.48 (1.36, 4.51)
Malaria No 1.00 (Ref.)c 0.01
Yes 0.52 (0.31, 0.87)
Severe anaemia No 1.00 (Ref.)c 0.05
Yes 0.57 (0.32, 0.99)
Level of consciousness Alert 1.00 (Ref.)c
Prostration 0.87 (0.38, 2) 0.78
Coma 4.29 (1.8, 10.24) 0.001
BUN (mmol/L) < 7.14 1.00 (Ref.)c < 0.001
≥ 7.14 3.13 (1.80, 5.43)
Age (months) ≥ 12 1.00 (Ref.)c < 0.001
< 12 3.37 (1.95, 5.82)
Gender Male 1.00 (Ref.)c 0.66
Female 1.11 (0.69, 1.81)
Site Mbale 1.00 (Ref.)c
Kilifi 2.16 (0.82, 5.75) 0.12
Mulago 2.73 (1.29, 5.78) < 0.01
Soroti 1.31 (0.58, 2.95) 0.52
Lacor 3.12 (1.19, 8.2) 0.02
Teule 2.93 (1.05, 8.22) 0.04
aWald test p values
bLC defined as a relative lactate decline ≥ 40% and/or lactate normalisation (lactate < 2.5 mmol/L) at 8 h of randomisation
cReference group
Fig. 2 ROC curve for mortality at 72 h of randomisation based on
logistic regression model for lactate clearance (LC) at 8 h. LC was
defined as a relative LC ≥ 40% and/or lactate normalisation (lactate
< 2.5 mmol/L) within the first 8 h of treatment
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advanced HIV infection, it did not use a pre-defined
treatment algorithm to target LC, and it did not report
adjusted OR for the association of interest.
Some other limitations of our study should be taken
into account. First, despite the optimal LC threshold or
the LC rate not having been clearly defined, many stud-
ies on LC in sepsis have used a relative clearance rate of
10–20% in repeated samples measured at 2- to 3-h inter-
vals during the first 6 h of resuscitation. Our definition
of LC criteria was based on published data [14, 18, 19],
the median LC value in our cohort, and the 8-h interval
between lactate samples. A more extreme or loose defin-
ition could have yielded slightly different results. More-
over, the fact that LC in the FEAST trial was calculated
at 8 h after randomisation for all participants prevents
one from determining the precise moment when lactate
normalisation or LC occurred for each individual. If
some of the participants cleared their lactate significantly
earlier than 8 h and that was associated with a better
outcome, the true effect of lactate normalisation/LC on
survival could be underestimated. However, 169/341
children (49.6%) died before 8 h, which again could have
resulted in a relevant underestimation of the study re-
sults. The key point is that we chose the 8-h correction
as this could be compared to other studies [26–28];
given the high proportion of mortality that occurred be-
fore this time point, an early assessment of LC may be
more relevant to this setting to identify high-risk patient
and initial resuscitation (either at 2 or 4 h). Lastly, LC
can be potentially useful when baseline HL exists, which
was not the case for one third of our participants.
Whilst lactate levels can falsely increase with haemoly-
sis, frequent with difficult phlebotomies or with long
time span from extraction to processing, blood samples
in the FEAST trial were obtained from a free-flowing
vein and immediately measured at the bedside. Arterial
lactates are recommended over peripheral venous lac-
tates in sepsis studies looking at absolute values and
clearance rate, due to poor agreement between both pa-
rameters [30]. Nevertheless, there are technical and eth-
ical challenges in obtaining arterial samples in un-
sedated children, and the strong prognostic correlation
with high admission venous lactate and LC with survival
outcomes suggests that pragmatically venous samples
should be suitable for critically sick children in resource-
limited hospitals. Lastly, lactate levels may increase with
hyperglycaemia, unrelated to a tissue oxygen debt but
related to a stress-induced increased glucose turnover.
This so-called type B lactic acidosis usually resolves
quickly after normalisation of glycaemia [31]. Only 6% of
participants in the analysis had hyperglycaemia on ad-
mission, so it is unlikely this would have introduced a
bias in the overall analysis. However, some evidence of
an effect modification was found between HL and
hyperglycaemia (see Additional file 1), with a weakened
association between HL and death in the presence of
hyperglycaemia.
Relevant to the FEAST Paediatric Emergency Triage
(PET) clinical score [5], which includes the presence of
crackles (lung crepitations) on auscultation as a predict-
ive maker of death, we too found that lung crepitations
in association with high lactate strongly predicts 72-h
mortality (OR 29.90; 95% CI 11.43–78.14) in children
with shock, which most likely indicates the aetiology was
sepsis due to pneumonia. This observation may help re-
fine definitions of severe pneumonia, which are broad
and non-specific. Interestingly, in the PET score analysis
hypoxaemia (pulse oximetry reading < 90%) did not in-
dependently predict poor outcome [5]. In this analysis,
hypoxaemia was found to be independently associated
with death at 72 h (OR 1.72, p = 0.01); however, as it did
not confound or modify the association between HL and
d72, it was not included in the logistic regression model.
Moreover, children septic with pneumonia (defined as
crackles on auscultation and presence of hyperlactatae-
mia) were more likely to suffer from hypoxaemia (OR =
2.58; p < 0.0001). Owing to the poor specificity of signs
for pneumonia, WHO promotes the use of pulse oxi-
meters to direct children with signs of pneumonia for
oxygen therapy. Yet, pulse oximetry remains poorly im-
plemented [32]. One example, therefore, of the utility of
the PET score and/or use of lactate screening at admis-
sion is using lung crepitations in the future to screen for
clinical trials examining novel therapies specifically for
pneumonia in those at high risk for poor outcome.
Lastly, our findings suggest that the predictive values
of lactate on admission for mortality are lower in chil-
dren without malaria (3.4 mmol/L) than for those with
malaria (5.2 mmol/L). This is important, as a detailed
pathogenesis of HL in septic shock and and in malaria is
still imperfectly understood and may actually differ.
Whereas in sepsis HL is mostly viewed as a result of an-
aerobic metabolism secondary to systemic hypoperfusion
[33], HL in malaria is likely an even more complex
phenomenon, involving additional factors like sequestra-
tion of parasitised erythrocytes in the microcirculation,
acute severe haemolytic anaemia, seizure activity, and
end-products of parasite metabolism [34–36]. We have
previously described the relationship between baselines
haemoglobin and lactate (Additional file 2). This likely
diverse pathogenesis of HL in bacterial sepsis and mal-
aria could have implied a different prognostic value for
mortality that would explain the different definitions of
HL used in studies of sepsis and malaria. Thus, while
the current consensus cut-off value for sepsis is a lactate
> 2 mmol/L [37], most studies on severe malaria, where
HL is particularly frequent and profound, use a lactate
cut-off of > 5 mmol/L, following the WHO definition
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criteria [38]. Our study indicates that appropriate lactate
cut-off values, lower for children without malaria, should
be included in the design of therapeutic algorithms for
early risk stratification of severely ill children admitted
to hospital in malaria-endemic areas.
Conclusions
In conclusion, severe HL, defined as a venous lactate level
≥ 5 mmol/L on hospital admission, is a strong risk factor
for death within the first 72 h in children with severe fe-
brile illnesses in east Africa, independently of the under-
lying diagnosis. Failure to clear lactate (relative LC ≤ 10%)
within 8 h is also strongly prognostic of death, which
could serve as a simple risk-stratification tool or a surro-
gate endpoint of mortality in clinical trials. Those children
able to normalise or clear their lactate by at least 40%
within 8 h have an improved chance of survival. An LC
measured at an earlier time point may have yielded even
more relevant results owing to the high mortality prior to
8 h that occurred in our cohort. Whether LC alone, or in
combination with other clinical markers, can be used as a
cost-effective therapeutic target to guide initial resuscita-
tion and ultimately improve clinical outcomes of severely
ill febrile children in malaria-endemic areas, where lack of
basic patient monitoring and intensive therapies is stand-
ard, remains uncertain. Given severe infection is the most
common cause of death in children under 5 years of age
in these settings, and that early and aggressive initial re-
suscitation is key for survival, this question warrants fur-
ther investigation. These data provide the rationale for a
clinical trial of lactate clearance as an early therapeutic re-
suscitation goal in children with severe infection in
malaria-endemic areas. We encourage the use of point-of-
care lactate testing whenever possible in limited-resource
settings to identify high-risk patients.
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